• Special Issue Topic

    Molecular Diagnosis and Personalized Therapy of Cancer

    Submission Deadline: May 31, 2024

    Guest Editors

    Prof. Monica Fedele E-Mail

    Research Director, Institute for Experimental Endocrinology and Oncology Gaetano Salvatore (IEOS), Department of Biomedical Sciences, National Research Council (CNR), Naples, Italy

    Prof. Andrea Vecchione E-Mail

    Full Professor of Pathologic Anatomy, University of Rome La Sapienza, c/o Azienda Ospedaliero-Universitaria Sant'Andrea, Rome, Italy

    About the Special Issue

    Cancer is a highly heterogeneous and dynamic disease that evolves from the accumulation of genetic and epigenetic mutations affecting key driver molecules responsible for the malignant and chemo-resistant phenotype.

    In recent years, there has been a groundbreaking expansion in technological advances and therapeutic innovations in cancer medicine. Cancer diagnostics have begun moving away from sole reliance on direct biopsy of tumor tissue for cancer detection, diagnosis, and treatment monitoring. Consequently, pathologists have flanked molecular diagnosis to the morphological approach to discriminate within each tumor type, specific subtypes with different clinical outcomes. As a result, the classification of tumors has changed to include both morphological and molecular criteria. For most cancer types, specific biomarkers have been characterized, which can predict the success of specific therapy and are themselves targets of the treatment. However, each of these factors is influenced by the unique genetic signature, which may affect the expressivity of the malignant phenotype and its response to pharmacological approaches. Therefore, it becomes increasingly imperative to personalize cancer treatment by tailoring the best treatment approach to the patient.

    With this special issue, we would like to summarize current knowledge on the latest molecular approaches to personalized cancer diagnosis and therapy and welcome any contribution, including original research articles, reviews, opinions, and hypotheses, which may open a discussion on new perspectives about this topic.

    Keywords: biomarker, targeted therapy, personalized cancer medicine, molecular signature

    Call for Papers

    Published Articles

    Open Access
    Original Article
    Evaluation of antitumor potential of an anti-glypican-1 monoclonal antibody in preclinical lung cancer models reveals a distinct mechanism of action
    Aim: The main objective of this study was to investigate the antitumor effect of a mouse anti-human glypican-1 (GPC1) monoclonal antibody (mAb) on non-small cell lung carcinoma (NSCLC) and associ [...] Read more.
    Minghua Li ... Qingyu Zhou
    Published: June 17, 2024 Explor Target Antitumor Ther. 2024;5:600–626
    DOI: https://doi.org/10.37349/etat.2024.00238
    Times Cited: 0
    Open Access
    Practical implications of androgen receptor inhibitors for prostate cancer treatment
    Antiandrogens have been used for the treatment of prostate cancer as a single agent or in combination with hormone deprivation therapy. New generation antiandrogens act like androgen receptor inhibi [...] Read more.
    Fabio Campodonico ... Carlo Introini
    Published: May 28, 2024 Explor Target Antitumor Ther. 2024;5:543–550
    DOI: https://doi.org/10.37349/etat.2024.00234
    Times Cited: 0
    Open Access
    Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors
    Thymic epithelial tumors (TETs) are rare malignant neoplasms arising in the thymus gland. Nevertheless, TETs, including thymomas (TMs), thymic carcinomas (TCs), and thymic neuroendocrine neoplasms ( [...] Read more.
    Stefano Lucà ... Renato Franco
    Published: May 21, 2024 Explor Target Antitumor Ther. 2024;5:465–476
    DOI: https://doi.org/10.37349/etat.2024.00229
    Times Cited: 0
    Open Access
    Case Report
    Improving single nucleotide polymorphisms genotyping accuracy for dihydropyrimidine dehydrogenase testing in pharmacogenetics
    Fluoropyrimidines, crucial in cancer treatment, often cause toxicity concerns even at standard doses. Toxic accumulation of fluoropyrimidine metabolites, culminating in adverse effects, can stem fro [...] Read more.
    Annalaura Montella ... Mario Capasso
    Published: April 24, 2024 Explor Target Antitumor Ther. 2024;5:374–383
    DOI: https://doi.org/10.37349/etat.2024.00223
    Times Cited: 0